Payment overview · 2025
General Payments
$1,949.23
107 reported records · 23 companies
Healthcare provider profile · identity verified
James Cornelius Wilson
Allopathic & Osteopathic Physicians|Family Medicine · WEST BROOKFIELD, MA · NPI 1285622365
Verified facts
What the public records show
CMS Open Payments records show James Cornelius Wilson received $1,949.23 in general payments during 2025 across 107 reported records.
Lundbeck LLC accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $438.02 | 22.5% | 23 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $259.28 | 13.3% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $214.89 | 11.0% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $206.72 | 10.6% | 20 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $166.76 | 8.6% | 7 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $124.87 | 6.4% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.47 | 5.6% | 7 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.79 | 2.4% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $44.37 | 2.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.16 | 2.1% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $39.80 | 2.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.60 | 1.8% | 2 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $33.29 | 1.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $24.74 | 1.3% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $24.47 | 1.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.10 | 1.2% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.67 | 1.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.64 | 0.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.16 | 0.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.95 | 0.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.93 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.71 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.84 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,842.01 | 97 |
| Education | $107.22 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $438.02 | 23 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $206.72 | 20 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $130.27 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $127.89 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $127.89 | 7 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $124.87 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $108.48 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $108.47 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $107.02 | 5 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $45.79 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $44.37 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $41.16 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.49 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.49 | 4 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $33.29 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $29.96 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
260 | 45 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 662 | 174 |
| Lisinopril | Lisinopril | 610 | 154 |
| Gabapentin | Gabapentin | 554 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 539 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 508 | 111 |
| Omeprazole | Omeprazole | 458 | 121 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 426 | 98 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 373 | 46 |
| Metformin Hcl | Metformin Hcl | 317 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 300 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 290 | 60 |
| Lorazepam | Lorazepam | 270 | 44 |
| Clonazepam | Clonazepam | 265 | 42 |
| Trulicity | Dulaglutide | 260 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 227 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 61 |
| Simvastatin | Simvastatin | 214 | 51 |
| Furosemide | Furosemide | 206 | 46 |
| Trazodone Hcl | Trazodone Hcl | 206 | 41 |
| Losartan Potassium | Losartan Potassium | 186 | 45 |
| Ibuprofen | Ibuprofen | 185 | 49 |
| Sertraline Hcl | Sertraline Hcl | 181 | 45 |
| Diazepam | Diazepam | 171 | 28 |
| Eliquis | Apixaban | 169 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 159 | 39 |
| Alprazolam | Alprazolam | 158 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 36 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 149 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 23 |
| Prednisone | Prednisone | 133 | 51 |
| Chlorthalidone | Chlorthalidone | 132 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 32 |
| Bupropion Xl | Bupropion Hcl | 131 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 125 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 116 | 23 |
| Ozempic | Semaglutide | 115 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 114 | 20 |
| Tramadol Hcl | Tramadol Hcl | 112 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 109 | 29 |
| Pregabalin | Pregabalin | 107 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 26 |
| Jardiance | Empagliflozin | 102 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 100 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 100 | 13 |
| Atenolol | Atenolol | 96 | 19 |
| Potassium Chloride | Potassium Chloride | 94 | 15 |
| Famotidine | Famotidine | 89 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 88 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 23 |
| Aripiprazole | Aripiprazole | 84 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 82 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 47 |
| Topiramate | Topiramate | 79 | 16 |
| Montelukast Sodium | Montelukast Sodium | 76 | 16 |
| Allopurinol | Allopurinol | 74 | 20 |
| Finasteride | Finasteride | 69 | 16 |
| Nystatin | Nystatin | 66 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 22 |
| Divalproex Sodium | Divalproex Sodium | 65 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 63 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | 11 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 62 | suppressed |
| Lamotrigine | Lamotrigine | 61 | 11 |
| Mirtazapine | Mirtazapine | 60 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 59 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 13 |
| Carisoprodol | Carisoprodol | 58 | suppressed |
| Carvedilol | Carvedilol | 57 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 56 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 12 |
| Meloxicam | Meloxicam | 52 | suppressed |
| Baclofen | Baclofen | 51 | 12 |
| Spironolactone | Spironolactone | 50 | 13 |
| Celecoxib | Celecoxib | 49 | 11 |
| Farxiga | Dapagliflozin Propanediol | 47 | 11 |
| Rexulti | Brexpiprazole | 46 | suppressed |
| Rytary | Carbidopa/Levodopa | 46 | suppressed |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 13 |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Ezetimibe | Ezetimibe | 43 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 29 |
| Lovastatin | Lovastatin | 42 | 12 |
| Sucralfate | Sucralfate | 42 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 42 | 13 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Glipizide | Glipizide | 37 | suppressed |
| Jantoven | Warfarin Sodium | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 12 |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lacosamide | Lacosamide | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 13 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Modafinil | Modafinil | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 13 | suppressed |
| Codeine Sulfate | Codeine Sulfate | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,949.23 · 107 records | Lundbeck LLC | AIRSUPRA, AUSTEDO XR, Auvelity, BRIXADI, CAPLYTA, Cologuard Collection Kit, FANAPT, FREESTYLE LIBRE 3, IBSRELA, INGREZZA, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, KISUNLA, MAVYRET, MOUNJARO, NUZYRA, OTEZLA, Ohtuvayre, QULIPTA, REPATHA, REXULTI, SPRAVATO, SUBLOCADE, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XHANCE, YUPELRI, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error